Exercise and Health Research Group, Sport Health and Performance Enhancement (SHAPE) Research Centre, School of Science and Technology., Nottingham Trent University, Nottingham, UK.
Nottingham Cystic Fibrosis and Chidlren's Respiratory Research Centre, University of Nottingham, Nottingham, UK.
Cochrane Database Syst Rev. 2023 Sep 27;9(9):CD015236. doi: 10.1002/14651858.CD015236.pub2.
Cystic fibrosis (CF) is a multisystem disease; the importance of growth and nutritional status is well established given their implications for lung function and overall survivability. Furthermore, it has been established that intestinal microbial imbalance and inflammation are present in people with CF. Oral prebiotics are commercially available substrates that are selectively utilised by host intestinal micro-organisms and may improve both intestinal and overall health.
To evaluate the benefits and harms of prebiotics for improving health outcomes in children and adults with CF.
We searched the Cochrane Cystic Fibrosis Trials Register compiled from electronic database searches and handsearching of journals and conference abstract books. We also searched the reference lists of relevant articles and reviews. Date of last search: 19 October 2022. We also searched PubMed and online trials registries. Date of last search: 13 January 2023.
Randomised controlled trials (RCTs) and quasi-RCTs assessing the efficacy of prebiotics in children and adults with CF. We planned to only include the first treatment period from cross-over RCTs, regardless of washout period.
We did not identify any relevant trials.
We did not identify any relevant trials for inclusion in this review.
AUTHORS' CONCLUSIONS: This review did not find any evidence for the use of prebiotics in people with CF. Until such evidence is available, it is reasonable for clinicians to follow any local guidelines and to discuss the use of dietary prebiotics with their patients. Large and robust RCTs assessing the dietary prebiotics of inulin or galacto-oligosaccharides or fructo-oligosaccharides, or any combination of these, are needed. Such studies should be of at least 12 months in duration and assess outcomes such as growth and nutrition, gastrointestinal symptoms, pulmonary exacerbations, lung function, inflammatory biomarkers, hospitalisations, intestinal microbial profiling, and faecal short-chain fatty acids. Trials should include both children and adults and aim to be adequately powered to allow for subgroup analysis by age.
囊性纤维化（CF）是一种多系统疾病；鉴于其对肺功能和整体生存率的影响，生长和营养状况的重要性已得到充分确立。此外，已经确定 CF 患者存在肠道微生物失衡和炎症。口服益生元是商业上可获得的底物，这些底物被宿主肠道微生物选择性利用，可能改善肠道和整体健康。
评估益生元改善 CF 儿童和成人健康结果的益处和危害。
我们从电子数据库搜索和期刊及会议摘要书籍的手工搜索中编制了 Cochrane 囊性纤维化试验登记册，并进行了检索。我们还检索了相关文章和综述的参考文献列表。最后检索日期：2022 年 10 月 19 日。我们还检索了 PubMed 和在线试验注册处。最后检索日期：2023 年 1 月 13 日。
评估益生元在 CF 儿童和成人中的疗效的随机对照试验（RCT）和准 RCT。我们计划仅纳入交叉 RCT 的第一个治疗期，无论洗脱期如何。
我们没有发现任何相关的试验。
我们没有发现任何相关试验纳入本综述。
本综述没有发现任何证据支持 CF 患者使用益生元。在有这种证据之前，临床医生遵循任何当地指南并与患者讨论使用饮食益生元是合理的。需要进行大型且稳健的 RCT，评估菊粉或半乳糖-低聚糖或果寡糖或其任何组合的饮食益生元，这些 RCT 的持续时间至少为 12 个月，并评估生长和营养、胃肠道症状、肺部恶化、肺功能、炎症生物标志物、住院、肠道微生物特征、粪便短链脂肪酸等结果。试验应包括儿童和成人，并旨在有足够的效力进行按年龄分组的亚组分析。
